Biocardia Inc (BCDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biocardia Inc (BCDA) has a cash flow conversion efficiency ratio of -0.636x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.67 Million) by net assets ($2.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biocardia Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Biocardia Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BCDA liabilities breakdown for a breakdown of total debt and financial obligations.
Biocardia Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocardia Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Urgent.ly Inc. Common Stock
NASDAQ:ULY
|
0.038x |
|
Truscott Mining Corporation Ltd
AU:TRM
|
-0.049x |
|
Acceleware Ltd
V:AXE
|
0.077x |
|
Decent Holding Inc Ordinary Shares
NASDAQ:DXST
|
-0.368x |
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
0.138x |
|
NetX Holdings Bhd
KLSE:0020
|
0.025x |
|
Multi Ways Holdings Ltd
NYSE MKT:MWG
|
0.214x |
|
EMC Public Company Limited
BK:EMC
|
0.209x |
Annual Cash Flow Conversion Efficiency for Biocardia Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Biocardia Inc from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see Biocardia Inc (BCDA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $837.00K | $-8.03 Million | -9.589x | -254.11% |
| 2023-12-31 | $-1.60 Million | $-9.97 Million | 6.222x | +388.22% |
| 2022-12-31 | $4.89 Million | $-10.56 Million | -2.159x | -116.07% |
| 2021-12-31 | $10.38 Million | $-10.37 Million | -0.999x | -55.05% |
| 2020-12-31 | $19.18 Million | $-12.36 Million | -0.644x | +83.83% |
| 2019-12-31 | $2.37 Million | $-9.45 Million | -3.985x | -36.53% |
| 2018-12-31 | $3.79 Million | $-11.07 Million | -2.919x | -274.52% |
| 2017-12-31 | $11.12 Million | $-8.67 Million | -0.779x | -190.51% |
| 2016-12-31 | $20.58 Million | $-5.52 Million | -0.268x | -1223.91% |
| 2015-12-31 | $13.87 Million | $331.00K | 0.024x | +51.08% |
| 2014-12-31 | $13.54 Million | $214.00K | 0.016x | +678.90% |
| 2013-12-31 | $13.31 Million | $27.00K | 0.002x | +108.70% |
| 2012-12-31 | $13.29 Million | $-310.00K | -0.023x | +90.19% |
| 2011-12-31 | $12.98 Million | $-3.09 Million | -0.238x | +81.76% |
| 2010-12-31 | $3.28 Million | $-4.28 Million | -1.304x | -301.89% |
| 2009-12-31 | $14.74 Million | $-4.78 Million | -0.325x | -28.78% |
| 2008-12-31 | $10.70 Million | $-2.70 Million | -0.252x | +67.22% |
| 2007-12-31 | $61.28K | $-47.12K | -0.769x | +85.32% |
| 2006-12-31 | $141.55K | $-741.46K | -5.238x | -103.10% |
| 2005-12-31 | $176.73K | $-455.82K | -2.579x | -231.63% |
| 2004-12-31 | $963.58K | $-749.42K | -0.778x | -338.65% |
| 2003-12-31 | $1.68 Million | $-297.66K | -0.177x | +24.45% |
| 2002-12-31 | $2.09 Million | $-491.22K | -0.235x | +47.81% |
| 2001-12-31 | $3.40 Million | $-1.53 Million | -0.450x | -103.53% |
| 2000-12-31 | $6.27 Million | $-1.38 Million | -0.221x | +51.39% |
| 1999-12-31 | $2.20 Million | $-1.00 Million | -0.455x | -120.78% |
| 1998-12-31 | $3.40 Million | $-700.00K | -0.206x | -68.82% |
| 1997-12-31 | $4.10 Million | $-500.00K | -0.122x | 0.00% |
| 1996-12-31 | $4.10 Million | $-500.00K | -0.122x | +96.68% |
| 1995-12-31 | $-71.75K | $263.39K | -3.671x | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more